Vacunas en adultos ¿y por qué no?

  • Pedro J. Tarraga López Medico Familia del EAP de Albacete
Palabras clave: -

Resumen

-

Citas

Immunization in immunocompromised host. En: Canadian Immunization Guide. National Advisory Committee on Immunization. Minister of Health. 6ª Ed. 2002.

Centers for Disease Control and Prevention.Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. MMWR 2000; 49 (RR-10):1-127.

Chin, J. Control of Communicable Diseases.American Public Health Association. J.Chin, editor. 17th Edition. 2000. (Publicación Científica y Técnica No.581).

Red Nacional de Vigilancia Epidemiológica.Centro Nacional de Epidemiología. Instituto de Salud Carlos III.

Gestal Otero JJ, Takkouche B, Blasco Huelva P. Infecciones respiratorias agudas. Gripe. En: Piedrola Gil. Medicina Preventiva y Salud Pública. Ed. Masson, 10ª Edición. 2001.

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2003-2004 influenza season. Wkly Epidemiolo Rec. 2003; 9:58-62.

Musher, DM. Streptococcus pneumoniae. En: Mandell, Douglas, Bennett, editors. Principles and Practice of Infectious Diseases. Fourth edition. 1995. New York, Churchill Livingston Inc.

Fedson D, Musher D, Eskola J. Pneumococcal Vaccine. En: Plotkin S, Orenstein W, editors. Vaccines, 3th Ed. Philadelphia. WB Saunders.Co:1999; 553-608.

Butler JC, Breiman RF, Lipman HB, Broome CV, Facklam RR. Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations. JAMA 1993. 270: 1826-1831.

Ortqvist A, Hedlund J, Burman L, et al. Randomized trial of 23 valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998. 351: 399- 403.

Moore RA, Wiffen PJ and Lipsky BA. Are pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BCM Family Practice 2000. 1(1). http://biomedcentral.com/1471-2296/1/1

Publicado
2018-01-04